Modified Immune Cell Loading for Robust HPV T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy methods for HPV-associated diseases are inefficient in generating a robust T cell response and modulating the immune system to effectively treat or prevent HPV-associated cancers and infections.
Innovation Solution
Generating modified immune cells by passing a cell suspension through a constriction to perturb the cells, allowing an HPV antigen and adjuvant to enter intracellularly, thereby enhancing the immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapy methods are used to stimulate immune response, then immune system activation is attempted, but the T cell response is insufficient and the immune modulation is ineffective against HPV-associated cancers
Solution Approach 1:
The patent embeds multiple functional components within dendritic cells: HPV antigens (E6, E7 proteins or mRNA) are loaded intracellularly along with adjuvants (CpG oligonucleotides, STING agonists). This nested arrangement allows the dendritic cells to simultaneously present multiple antigens and provide multiple adjuvant signals, creating a potent immunogenic environment that overcomes the insufficiency of conventional single-antigen vaccines
Solution Approach 2:
The patent transforms the dendritic cells through physical deformation (passing through constrictions) and chemical modification (loading with antigens and adjuvants). This changes the cellular parameters including membrane permeability, antigen presentation capacity, and cytokine production profile, converting ordinary dendritic cells into highly immunogenic modified dendritic cells capable of eliciting robust T cell responses
2Reliability
If multiple immunotherapy approaches are combined to enhance immune response, then broader immune coverage is achieved, but treatment complexity and manufacturing difficulty increase
Solution Approach 1:
The patent merges multiple therapeutic functions into a single modified dendritic cell product: multiple HPV antigens (E6, E7), multiple adjuvants (CpG, STING agonists), and antigen-presenting machinery are all combined within one cell type. This consolidation achieves comprehensive immune coverage against different HPV strains and epitopes while simplifying the therapeutic regimen compared to administering multiple separate vaccines or cell products
Solution Approach 2:
The modified dendritic cells serve multiple functions simultaneously: they act as antigen presenters, adjuvant deliverers, T cell activators, and cytokine producers. This multi-functionality allows a single cell product to replace what would traditionally require multiple different therapeutic agents, reducing overall treatment complexity despite the enhanced immunogenicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified immune cells induce a robust T cell response, activating cytotoxic and helper T cells to target and destroy HPV-infected cells, effectively treating and preventing HPV-associated diseases.
Implementation Method 1
passing a cell suspension through a constriction to perturb the cells, allowing an HPV antigen and adjuvant to enter intracellularly
Data Source
AI summary
The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and/or for modulating an immune response in an individual with an HPV-associated disease.